Background: There is currently no simple scoring system to evaluate change in symptoms during a pulmonary exacerbation (PEx) in adult cystic fibrosis (CF) patients. Patients and methods: We evaluated 265 episodes in 58 adult CF patients. A simple symptom score was administered at the start and the end of each PEx. The score evaluated four symptoms: cough, sputum, breathlessness and fatigue. Each symptom was scored from one (mild symptoms) to four (severe symptoms). The total symptom score was the summation of all the four symptoms. The total symptom score was compared with CF Respiratory Questionnaire (CFRQ) and with spirometry. Results: There was significant internal correlation between scores for each pair of symptoms. The total
Introduction
Pulmonary exacerbations (PExs) in cystic fibrosis (CF) are an important feature of the disease. [1] [2] [3] Frequency of PExs is associated with accelerated decline in lung function tests, 4 impaired quality of life 5 and premature mortality. 6 In practice, assessment of outcome of treatment in PExs is usually made by routine questioning during a clinical consultation and by spirometry.
Currently, available multi-dimensional qualityof-life questionnaires in CF 7, 8 are mainly used in monitoring of long-term interventions. Due to their length and complexity, they are not used in daily practice to evaluate the outcome of treatment with intravenous (IV) antibiotics and cannot be used as self-reporting tool on a paper of electronic diaries.
The need to establish robust patient-related outcome in CF and to link it with biochemical measurements was expressed by the Working Group for Patient-Reported Outcomes for CF people. 9 The group put a particular emphasis on finding appropriate end points that could be used in clinical trials. 10 There was also a notable quest to find a consensus definition of CF PExs. Implicitly, this goal would indicate the need for a validated method to quantify symptoms during and after treatment of PExs.
A short, validated numerical score for respiratory symptoms would be useful in evaluating the course of CF PExs and with the decision to extend the treatment period beyond the conventional 14 days. It could also be used by patients for daily monitoring in paper or electronic diaries. 11 In clinical trials of new interventions specifically used during CF PExs (such as new antibiotics or physiotherapy techniques), a score that was sensitive to change over the short course of treatment would be a valuable tool to add to lung function tests, sputum volume and other biomarkers.
This research was set out to examine the value of a new simple and practical scoring system that could be used in daily practice by health professionals during acute CF PExs.
Our hypothesis was that our scoring system was sensitive to change after treatment of PExs and would correlate with lung function tests and other validated CF quality-of-life scores. We also hypothesized that a change of score from the start to the end of treatment would correlate with the change in lung function tests.
Methods and Patients
The symptom score At Bristol Royal Infirmary and from 2007 to 2009, we conducted a prospective research programme with the objective to examine and define the natural history of CF PExs in adult CF patients. The programme was approved by the Southmead Research Ethics Committee. All CF patients signed an informed consent prior to being involved in the study. Evaluation of the symptom score was one aspect of this programme.
The symptom score was previously used to evaluate daily electronic telemonitoring of adult CF patients and patients with chronic obstructive pulmonary disease (COPD). [11] [12] [13] Choice of PEx symptoms was obtained through a national survey for all adult CF units in UK, the results of which were published in an abstract form.
14 In this survey, the four most frequently encountered symptoms during PExs as reported by adult CF physicians were cough, sputum volume and viscosity, breathlessness and fatigue.
The phrases for each symptom were adapted from, although were not identical to, the Medical Research Council (MRC) respiratory symptom score. 15 The MRC score did not include fatigue. The fatigue score was, therefore, extrapolated from the breathlessness score. Each symptom score ranged from one (no symptom) to four (severe symptoms). The total symptom score was the summation of individual scores for each one of the four symptoms. Higher scores indicated more severe clinical picture. Table 1 shows the scoring criteria for each symptom.
Inclusion criteria were consenting adult CF patients receiving full care in our unit who were about to start on IV antibiotic treatment for a PEx. Exclusion criteria were patients on a shared care treatment regimen with other units and post-lung transplant patients.
The symptom score was administered by a CF clinician (a doctor or CF nurse specialist) at the start and on Day 14 of each PEx that required a course of IV antibiotics.
For the purpose of the validation process of the score, we chose only exacerbations that needed administration of IV antibiotics. PExs were defined as 'an event in the course of the disease when an increase in symptoms was felt beyond day-today fluctuations for the patient, which instigated treatment with IV antibiotics'. Mild exacerbations requiring oral antibiotics were excluded from the analysis.
Spirometry was performed at the start of treatment and on Day 14. All spirometry measurements were performed by qualified and experienced lung physiologists, unaware of the purpose of the study, and according to the recommendations of the British Thoracic Society/Association of Respiratory Technicians and Physiologists (BTS/ARTP) guidelines. 16 Measurements included forced expiratory volume in the first second (FEV1) and forced vital 17 the reference values for spirometry for young adult patients in the age group of our CF patients remain contentious. 18 In order to examine within-patient variation of the total symptom score, we assessed the difference of the total symptom score in the same patient at the start of treatment and at the end of the treatment in two successive exacerbations.
To compare the symptom score with existing quality-of-life tools, patients completed the Quittner's adult CF Respiratory Questionnaire (CFRQ). 7 This is a disease specific multi-dimensional questionnaire. Item scoring was obtained by kind permission of Professor Quittner. Comparisons were made between our total symptom score with three individual components of CFRQ: the summary score (calculated from adding the scores of all domains), the score of physical functioning component and the score of respiratory symptom component.
The change in total symptom score between the start and the end of treatment with antibiotics was calculated by subtraction of the total symptom score on Day 1 from that on Day 14. A similar method was used to calculate the change in spirometry measurements and CFRQ scores.
Validation of the symptom score
The validation of the symptom score as well as the statistical analyses for this research was done with the help of the Department of Biomedical Statistics at the Bristol Royal Infirmary. Spearman's correlation test was applied for all correlations.
The validation process of the symptom score was made using six steps as follows.
Step 1. Examination of frequency of appearance of each score for each symptom. We elected that if a score for any individual symptom was reported by >75% of cases or by <10% of cases this would be regarded as non-discriminatory and should be considered for re-assessment of the terminology used in that specific score. This was similar to the principles used by Jones et al. 19 in the COPD Assessment Test score (CAT score), where the items elected by only few people were ruled out as being below the 'floor' limit and items chosen by most patients were also ruled out as they exceeded the 'ceiling' limit.
Step 2. Assessment of the internal correlation between scores of pairs of individual symptoms.
Step 3. The degree of correlation of our total score with the three components of the CFRQ as described above.
Step 4. Examination of the correlation of the total symptom score with FEV1 and FVC.
Step 5. Assessment of the sensitivity of the total symptom score to change after the 14-day treatment period.
Step 6. The degree of correlation of the change in symptom score with change in spirometry values after the 14-day treatment period.
Results
A total of 58 adult CF patients (26 female) were included in the study. A total of 265 symptom scores from 136 acute exacerbations were calculated (136 on Day 1 of antibiotic treatment and 129 on Day 14) . In seven, PExs assessment was not available on Day 14 as patients did not attend. Patient demographics are outlined in Table 2 .
When comparing the start of the first exacerbation with the start of the second exacerbation, the total score differed in 82% of patients. The total score also differed by the same proportion (82%) at the end of first exacerbation with the end of second exacerbation. The within patient variation was, therefore, considered significant enough to allow the use of each exacerbation as a separate entity. Table 3 shows the frequency of each score for each individual symptom. Individual symptom score below the 10% limit (floor effect) was encountered only for the score 1 in cough (no cough) and score 1 in sputum (no sputum), but not for breathlessness or fatigue. The descriptive phrases for these scores are, therefore, considered to need revision. None of the remaining scores for each individual symptom fell below 10%. None of the scores for any symptom exceeded 75% limit (ceiling effect).
There were significant internal correlations between scores of all pairs of symptoms ( Table 4) . The strongest correlation was between the cough score and the sputum score and the weakest was between the sputum score and the breathlessness score.
The total symptom score inversely correlated with the CFRQ scores as follows: r = À0.47 for the summary score, r = À0.64 for the score of the physical functioning domain and r = À0.62 for the respiratory symptom domain, P < 0.0001 for all correlations. The inverse nature of correlation was due to the fact that a higher score on the CFRQ indicated better health status whereas higher scores on our scoring system indicated more severe symptoms.
Total symptom score inversely correlated with FEV1 (r = À0.41, P < 0.0001) and FVC (r = À0.41, P < 0.0001).
Symptom score improved in 88.3% of the cases and was either unchanged or worsened in the remaining cases (Table 5 and Figure 1) . Changes in the total symptom score after the course of IV antibiotic treatment (from Day 1 to Day 14) correlated with changes in FEV1 and FVC (Figure 2 ).
Discussion
This paper describes a simple symptom score, which evaluates common respiratory symptoms and has been validated in adult CF patients for use during PExs; the acute phase of the disease. The score is The proportion is the frequency out of the total episodes for each symptom; for example, the proportion of score 1 for cough is 26 divided by 265. (Number of episodes: pre-treatment: 136, post-treatment: 129, total 265). Table 5 Change in the total symptom score at the end of exacerbation (please see Figure 2 for comparison with change in FEV1 and FVC)
Increased (symptom worsened) 6 (4.4%) Unchanged 10 (7.3%) Reduced by one-point value 11 (8.0%) Reduced by >one-point value 109 (80.3%)
simple and quick to administer by an operator (as the case in this research) and is short enough to be self-administered by patients. 11 The simplicity of this score is one of its strengths. The current score is not a global patient-related outcome, in that it does not include items that evaluate other characteristics such as mood, sleep, work absenteeism or general impairment of activities. Nevertheless, the method of establishing the score meets many of the criteria set out by the FDA guidance on developing patient reported outcomes. 9, 10 In addition, we previously used the score on a Personal Digital Assistant device for daily recording of symptoms in a study that was designed to evaluate distant daily telemonitoring of CF and COPD patients. [11] [12] [13] As first step of evaluating the score, we examined the closeness of correlations of each item with others. The close internal correlation between components of the score, while not surprising, is encouraging and although this may be predictable, this study is the first to show a correlation between each pair of symptoms. This close correlation would suggest that weights of individual components could be regarded to be similar. Other encouraging results were the close correlation of our symptom score with corresponding scores of the widely used but a longer CFRQ. In this study, we did not examine the changes in symptom score from disease stability. But we showed that the symptom score was sensitive to change after treatment with IV antibiotics. Total score decreased (symptoms improved) by at least one point in >88% of episodes and by >one point in >80% (Table 5 and Figure 1) .
Similar steps needed to develop patient-reported outcome was outlined by Quittner et al. 20 who discussed identification of Minimal Clinically Important Difference (MCID) score in a proposed modification of her CFRQ in children, adolescents and young CF adults participating in prospective clinical trials. Notably, the purpose of this modified score was to be applied for trials running over long period of time rather than during exacerbations per se.
Choosing the degree of change in our symptom score that might signify a start of a PEx or recovery from a PEx is a matter for each clinician to consider. Based on the finding discussed above and given the small number of possible responses in our scoring system (total 16 responses for the four items), we would suggest that an improvement of more than one point after 2-week treatment with IV antibiotics could signify the MCID for a favourable response to treatment. Conversely, and although not examined in this study, a worsening of more than one point in the total score from the score during disease stability is proposed (together with other clinical indicators) to define a CF PEx. We recognize that clinicians who may use our scoring system might choose different MCID for diagnosis and/or recovery from PExs according to patients' clinical or demographic circumstances.
The degree of change that would suggest the diagnosis or recovery from exacerbation was carefully considered in a validated scoring test of 40 points (eight stem with five items per each stem) in COPD patients. 19 In that test, a change of two points over the assessment period was recommended to be MCID. In other words, an increase of two points in the score above that in disease stability was suggested to support the clinical diagnosis of acute COPD exacerbation and conversely, a reduction of the score by two points after treatment was suggested to define the end of exacerbation.
In our study, in <10% of responses, patients reported the lowest scores for cough (no cough) and sputum (no sputum) the so-called floor effect. Similar results were not found for fatigue and breathlessness. This is probably because cough and sputum are prominent symptoms even in disease stability and would remain present even at the end of PExs. We, therefore, would propose to change the wording in the lowest scores for cough and sputum as follows: score 1 for cough to be 'cough occasionally' (instead of no cough) and for sputum to 'morning or occasional sputum' (instead of no sputum).
The consensus document on CF exacerbation by the US CF Foundation 21 suggested that an exacerbation should be considered to be present when a combination of symptoms and signs (typically three or more) were present. The list of symptoms did not have a scoring system attached to it, and the range of symptoms in the list appeared to be more relevant to paediatric than to adult CF patients. In addition, this definition chose the number of symptoms but gave no regard to the intensity of each symptom. The symptom list, although used in several notable clinical trials, 22, 23 was seen to need an improvement with a better validated system. 9, 10 In a pivotal work pioneered by the US CF Foundation and the Food and Drugs Administrations (FDA), defining CF exacerbation was one of the goals that have been tasked to the CF community. 10 A more recent venture that addressed patient-reported outcomes in clinical trials in CF, another working group from the US CF Foundation, identified definition of CF PExs to be an important goal. 9, 10 As discussed earlier, the scoring system outlined in this paper (with minor modifications) would useful to be an additional practical tool to be used to define CF PEx or to determine the outcome of treatment of CF PEx.
